Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Goldstein (1990)
Physicians and the pharmaceutical industry.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 146 3
D. Rennie, A. Flanagin (1994)
Authorship! Authorship! Guests, ghosts, grafters, and the two-sided coin.JAMA, 271 6
B. Psaty, R. Kronmal (2008)
Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.JAMA, 299 15
C. Deangelis (2005)
Rainbow to dark clouds.JAMA, 294 9
GP Geba, AL Weaver, AB Polis (2002)
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee., 287
C. Deangelis, P. Fontanarosa, A. Flanagin (2001)
Reporting financial conflicts of interest and relationships between investigators and research sponsors.JAMA, 286 1
F. Silverstein, G. Faich, J. Goldstein, L. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N. Agrawal, W. Stenson, A. Burr, William Zhao, J. Kent, J. Lefkowith, K. Verburg, G. Geis (2000)
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.JAMA, 284 10
D Carlat
Dr drug rep.
J. Ross, K. Hill, D. Egilman, H. Krumholz (2008)
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.JAMA, 299 15
D. Healy, D. Cattell (2003)
Interface between authorship, industry and science in the domain of therapeuticsBritish Journal of Psychiatry, 183
M. Steinman, L. Bero, M. Chren, C. Landefeld (2006)
Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry DocumentsAnnals of Internal Medicine, 145
Uniform requirements for manuscripts submitted to biomedical journals.
A. Wazana (2000)
Physicians and the pharmaceutical industry: is a gift ever just a gift?JAMA, 283 3
B. Vastag (2008)
Reviewer leaked Avandia study to drug firmNature, 451
MA Steinman, LA Bero, MM Chren, CS Landefeld (2006)
Narrative review: the promotion of gabapentin., 145
D. Solomon, J. Avorn (2005)
Coxibs, science, and the public trust.Archives of internal medicine, 165 2
Scientific Therapeutics Information Inc Web site.
G. Curfman, S. Morrissey, J. Drazen (2005)
Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.The New England journal of medicine, 353 26
Catherine Deangelis, J. Drazen, F. Frizelle, C. Haug, J. Hoey, R. Horton, S. Kotzin, C. Laine, A. Marušić, A. Overbeke, T. Schroeder, Harold Sox, M. Weyden (2004)
Clinical trial registration: a statement from the International Committee of Medical Journal Editors.JAMA, 292 11
G. Geba, A. Weaver, A. Polis, M. Dixon, T. Schnitzer (2002)
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.JAMA, 287 1
R. Steinbrook (2008)
Financial support of continuing medical education.JAMA, 299 9
FE Silverstein, G Faich, JL Goldstein (2000)
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis., 284
P. Fontanarosa, A. Flanagin, C. Deangelis (2005)
Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies.JAMA, 294 1
N. Choudhry, H. Stelfox, A. Detsky (2002)
Relationships between authors of clinical practice guidelines and the pharmaceutical industry.JAMA, 287 5
S. Fletcher (2008)
Chairman's summary of the conference. Continuing education in the health professions: improving healthcare through lifelong learning.Journal of continuing education in nursing, 39 3
CD DeAngelis, JM Drazen, FA Frizelle (2004)
Clinical trial registration., 292
Editorials represent the opinions EDITORIAL of the authors and JAMA and not those of the American Medical Association. The Adverse Effects of Industry Influence tonotethatforsomeofthereferencedpublicationslistedinthe Catherine D. DeAngelis, MD, MPH Table of the article by Ross et al, some of the authors either did Phil B. Fontanarosa, MD, MBA not actually receive financial support from the company; were not required by the journal in which the study was published HE PROFESSION OF MEDICINE, IN EVERY ASPECT— todisclosetheirfinancialsupportorrelationshipwiththespon- clinical, education, and research—has been inun- sor; did report their financial support or relationship with the dated with profound influence from the pharma- sponsor, but the journal chose not to publish those author dis- Tceutical and medical device industries. This has closures; or did disclose their financial support, and those dis- occurred because physicians have allowed it to happen, and closures were published. it is time to stop. However, it is clear that at least some of the authors played 1,2 Two articles in this issue of JAMA provide a glimpse of little direct roles in the study or review, yet still allowed them- one company’s apparent misrepresentation of research data selves to be named as authors. Individuals, particularly phy- and its
JAMA – American Medical Association
Published: Apr 16, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.